Certolizumab is excreted into breastmilk in some, but not all, women in small amounts. It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[1] Anti-TNF agents appear to reduce the levels of tumor necrosis factor and IP-10 in the milk of mothers with inflammatory bowel disease in the early postpartum period.[2] Polyethylene glycol is not excreted into breastmilk.[3] Numerous experts and professional guidelines have stated that the drug is a low risk to the nursing infant and acceptable to use during breastfeeding.[4-12]
在部分而非所有女性中，赛妥珠单抗会少量排泄到母乳中。它也可能在婴儿胃肠道中被部分破坏，婴儿对其吸收可能极少。[1]抗TNF药物似乎会降低产后早期患有炎症性肠病的母亲乳汁中肿瘤坏死因子和IP - 10的水平。[2]聚乙二醇不会排泄到母乳中。[3]众多专家和专业指南指出，该药物对哺乳婴儿的风险较低，母乳喂养期间使用是可接受的。[4 - 12]
